| scholarly article | Q13442814 |
| P2093 | author name string | Andreas Port | |
| Arne Ring | |||
| E Ulrike Graefe-Mody | |||
| Ivette Revollo | |||
| Klaus A Dugi | |||
| Mario Iovino | |||
| P2860 | cites work | 8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes | Q27649174 |
| A thorough QTc study to assess the effect of sitagliptin, a DPP4 inhibitor, on ventricular repolarization in healthy subjects | Q33482122 | ||
| Facts, fancies and follies of drug-induced QT/QTc interval shortening | Q33661036 | ||
| Cardiac effects of ebastine and other antihistamines in humans | Q33794485 | ||
| Mixed models for data from thorough QT studies: part 1. assessment of marginal QT prolongation. | Q33901132 | ||
| Enhancing Incretin Action for the Treatment of Type 2 Diabetes | Q35545683 | ||
| QT Prolongation and Fatal Arrhythmias: A Review of Clinical Implications and Effects of Drugs | Q35587365 | ||
| A definitive or thorough phase 1 QT ECG trial as a requirement for drug safety assessment | Q35767175 | ||
| Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans | Q35844598 | ||
| Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes? | Q35871904 | ||
| Rationale for dipeptidyl peptidase 4 inhibitors: a new class of oral agents for the treatment of type 2 diabetes mellitus | Q36693199 | ||
| Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitus | Q36892807 | ||
| Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes | Q37641377 | ||
| Statistical characterization of QT prolongation | Q39207528 | ||
| Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes. | Q42831059 | ||
| Statistical models for heart rate correction of the QT interval | Q43698333 | ||
| Effects of three fluoroquinolones on QT interval in healthy adults after single doses | Q44413098 | ||
| Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients. | Q45992738 | ||
| Period correction of the QTc of moxifloxacin with multiple predose baseline ECGs is the least variable of 4 methods tested | Q46087923 | ||
| Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of BI 1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers | Q46350665 | ||
| (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared wi | Q46788948 | ||
| Statistical issues including design and sample size calculation in thorough QT/QTc studies | Q47234237 | ||
| A maximum likelihood approach for estimating the QT correction factor using mixed effects model | Q47903088 | ||
| Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study. | Q51376974 | ||
| Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. | Q51382786 | ||
| Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. | Q51385774 | ||
| Differences between study-specific and subject-specific heart rate corrections of the QT interval in investigations of drug induced QTc prolongation. | Q51996341 | ||
| Bias and variance evaluation of QT interval correction methods. | Q53038113 | ||
| International Conference on Harmonisation; guidance on E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs; availability. Notice. | Q53265213 | ||
| Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects | Q57314101 | ||
| Design and analysis considerations for thorough QT studies employing conventional (10 s, 12-lead) ECG recordings | Q87070578 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | linagliptin | Q909745 |
| P304 | page(s) | 39-50 | |
| P577 | publication date | 2011-07-01 | |
| P1433 | published in | British Journal of Clinical Pharmacology | Q176044 |
| P1476 | title | The DPP-4 inhibitor linagliptin does not prolong the QT interval at therapeutic and supratherapeutic doses | |
| P478 | volume | 72 |
| Q57093598 | Cardiovascular Safety of Antihyperglycemic Agents: "Do Good or Do No Harm" |
| Q34638128 | Clinical pharmacokinetics and pharmacodynamics of linagliptin. |
| Q38546981 | Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus |
| Q38200670 | Dipeptidyl peptidase-4 inhibitors: pharmacokinetics, efficacy, tolerability and safety in renal impairment. |
| Q35752928 | Efficacy and safety of linagliptin (tradjenta) in adults with type-2 diabetes mellitus. |
| Q38577303 | Empagliflozin/Linagliptin: A Review in Type 2 Diabetes |
| Q38828606 | Evogliptin: a new dipeptidyl peptidase inhibitor for the treatment of type 2 diabetes |
| Q50858150 | FAP finds FGF21 easy to digest. |
| Q36636639 | Linagliptin: A thorough Characterization beyond Its Clinical Efficacy |
| Q38036742 | Linagliptin: a review of its use in the management of type 2 diabetes mellitus |
| Q38258278 | Linagliptin: an update of its use in patients with type 2 diabetes mellitus |
| Q38108636 | Linagliptin: farmacology, efficacy and safety in type 2 diabetes treatment |
| Q37858521 | Linagliptin: in type 2 diabetes mellitus |
| Q36087961 | Pharmacokinetics of linagliptin in subjects with hepatic impairment |
| Q38134902 | The cardiovascular safety of incretin-based therapies: a review of the evidence |
Search more.